Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

Science Spotlight: Killing the mesenchymal precursors that drive cancer progression

BioCentury’s roundup of translational innovations also includes blood detection of pregnancy complications, BBB-crossing antibodies, and more

March 12, 2025 11:21 PM UTC

Selective ablation of cancer cells with a spindle-like morphology that undergo an epithelial-to-mesenchymal (EMT) transition could prevent pancreatic cancer progression, suggests a Nature study led by researchers at University of Texas MD Anderson Cancer Center.

Using lineage-tracing and a lineage-ablation system in a genetically engineered mosaic mouse model of pancreatic cancer, the authors identified and selectively targeted tumor cells derived from mesenchymal cancer cells, resulting in increased survival and decreased tumor growth and metastasis. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article